# Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

> **NCT02397694** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 98 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** BIC
- **DRUG:** F/TAF
- **DRUG:** DTG
- **DRUG:** BIC Placebo
- **DRUG:** DTG Placebo
- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT02397694
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-23
- **Primary completion:** 2015-11-30
- **Final completion:** 2019-02-27
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02397694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02397694, "Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02397694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*